Christopher Martenson

Christopher Martenson
Born 15 September 1962 (1962-09-15) (age 49)
Nationality USA
Known for Former Vice President of Pfizer, Inc. and Science Applications International Corporation

Christopher Hamlin Martenson is an former American biochemical scientist and Vice President of Pfizer.[1] Currently he is an author and trend forecaster interested in macro trends regarding the economy, energy composition and environment.[2]

Contents

Education and career in the pharmaceutical industry

Martenson received his PhD degree in neurotoxicology at Duke University in 1994 with his doctoral thesis Acrylamide neurotoxicity: effect on neuronal growth cones and axonal fast transport, and furthermore completed a post-doctoral programme at the same university in 1995–1997 where he specialised in neuronal signal transduction and transport. He also obtained an MBA degree from Cornell University in 1998 and is a fellow of the Post Carbon Institute.[3]

He performed research fo many years in biochemistry, neurotoxicology, applied pharmacology and in vitro techniques. Martenson was Consultant In Business Development and Strategies at Pfizer, Inc. Later he became the Vice President of the company, and later still – a Vice President of Science Applications International Corporation's Life Sciences Division,[4] which position he held till July 2005.

Career in economic macro trending

In more recent years Martenson stepped away from biological sciences and management to develop an educational video seminar series called The Crash Course (originally published in October 2008) based on neo-malthusian concepts. The course investigates the ways in which the economy, the environment and energy are interlinked and interact.

The Crash Course has since been expanded updated into a book for 2011, also titled "The Crash Course: The Unsustainable Future Of Our Economy, Energy, And Environment". http://www.amazon.com/Crash-Course-Unsustainable-Economy-Environment/dp/047092764X

Publications

  1. Axonal transport: beyond kinesin and cytoplasmic dynein, Current opinion in neurobiology, 1991–Oct, vol. 1 (issue 3): pp. 393–398
  2. Fast axonal transport is required for growth cone advance, Nature, 366, 66–69 (4 November 1993)
  3. Acrylamide neurotoxicity: effect on neuronal growth cones and axonal fast transport, a Duke University thesis, Ph.D. M377A 1994 LSC.
  4. In Vitro Acrylamide exposure alters growth cone morphology, Toxicology and Applied Pharmacology, Volume 131, Issue 1, March 1995, pp. 119–129
  5. The effect of acrylamide and other sulfhydryl alkylators on the ability of Dynein and Kinesin to translocate microtubules in Vitro, Toxicology and Applied Pharmacology, Volume 133, Issue 1, July 1995, pp. 73–81
  6. Calmodulin dynamics within intact hippocampal cells, Duke University, 1F32NS010263-01 (1996)
  7. Inhibition of Lyn function in mast cell activation by SH3 domain binding peptides, Biochemistry, 1997, 36 (31), pp. 9388–9394
  8. Internal trafficking and surface mobility of a functionally intact beta 2-adrenergic receptor – green fluorescent protein conjugate, Molecular Pharmacology, 51:177–184 (1997)
  9. Cornell equity research of ArQule, Inc., Cornell University, 17 November 1997

References

  1. ^ About Chris Martenson - website chrismartenson.com
  2. ^ Profile Chris Martenson - website Amazon.com
  3. ^ Fellow biographies, Post Carbon Institute
  4. ^ SAIC chooses Arcot for strong authentication, Marketwire, June 2003

External link